Plain-English translation of NCT06257394 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing the best way to treat children with very high-risk acute lymphoblastic leukemia (ALL)—a serious type of blood cancer. The study uses a combination of chemotherapy drugs and, for some patients, a targeted medication called Dasatinib that specifically attacks leukemia cells with a particular genetic change. The treatment plan is personalized based on how well the leukemia responds to the initial therapy and what the doctors find when they check for remaining cancer cells.
Children with very high-risk ALL have a poorer chance of recovery with standard treatments. This trial exists to find the best combination of chemotherapy and targeted medications to improve survival and cure rates for these vulnerable young patients in Korea.
You likely qualify if…
You likely don't qualify if…
If your child is enrolled, they will receive intensive chemotherapy given in phases over about 2–3 years. Depending on whether they have the Philadelphia chromosome genetic change and how well they respond to early treatment, they may receive Dasatinib (a targeted pill) along with chemotherapy, and they may eventually need a stem cell transplant. Throughout treatment, your child will have frequent hospital visits for infusions, blood tests, and bone marrow tests to monitor how the leukemia is responding and adjust the plan as needed.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
South Korea